Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
NCT ID NCT06824155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called 177Lu-RAD202, which is a radioactive antibody designed to seek out and deliver radiation directly to HER2-positive cancer cells. The study involves 30 adults with advanced solid tumors that have not responded to standard treatments. First, participants receive a small imaging dose to see where the drug goes in the body, then a treatment dose to check safety and find the best dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-RAD202 (a radioactive antibody that targets HER2 on cancer cells)
- What this could lead to
- If it works, this could lead to a new targeted treatment option for people with advanced HER2-positive solid tumors that have stopped responding to other therapies.
- What could go wrong
- This is a very early (Phase 0/1) and small trial with only 30 participants. The main goal is safety and dosing, not yet effectiveness. There are risks from radiation exposure to healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GenesisCare Murdoch
RECRUITINGMurdoch, Western Australia, 6150, Australia
-
Macquarie University Hospital
RECRUITINGMacquarie Park, New South Wales, 2109, Australia
-
Nepean Hospital
RECRUITINGKingswood, New South Wales, 2747, Australia
-
St Vincents Hospital, Melbourne
NOT_YET_RECRUITINGFitzroy, Victoria, 3065, Australia
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.